Viridian Therapeutics, Inc.
VRDN· Nasdaq
VRDNViridian Therapeutics, Inc.
Filed Mar 24, 2017 · 10-K · 83 days after period end · 0001171843-17-001747
| Metric | Q4 2016 | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures | Q4 2013dderived from reported figures |
|---|---|---|---|---|
| Revenue | $509.00K | $1.60M | $1.51M | — |
| Net Income | -$5.97M | -$2.98M | -$2.26M | — |
| EPS Diluted | -$9.20 | — | — |
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2016 · filed Mar 24, 2017 · 83 d after period end
